FR22C1037I2 - Procedes de glycoconjugaison et compositions - Google Patents

Procedes de glycoconjugaison et compositions

Info

Publication number
FR22C1037I2
FR22C1037I2 FR22C1037C FR22C1037C FR22C1037I2 FR 22C1037 I2 FR22C1037 I2 FR 22C1037I2 FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 C FR22C1037 C FR 22C1037C FR 22C1037 I2 FR22C1037 I2 FR 22C1037I2
Authority
FR
France
Prior art keywords
glycoconjugation
compositions
methods
glycoconjugation methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1037C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of FR22C1037I1 publication Critical patent/FR22C1037I1/fr
Application granted granted Critical
Publication of FR22C1037I2 publication Critical patent/FR22C1037I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FR22C1037C 2012-08-16 2022-07-28 Procedes de glycoconjugaison et compositions Active FR22C1037I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
PCT/IB2013/056597 WO2014027302A1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Publications (2)

Publication Number Publication Date
FR22C1037I1 FR22C1037I1 (fr) 2022-09-09
FR22C1037I2 true FR22C1037I2 (fr) 2023-05-26

Family

ID=49385307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1037C Active FR22C1037I2 (fr) 2012-08-16 2022-07-28 Procedes de glycoconjugaison et compositions

Country Status (32)

Country Link
US (6) US9517274B2 (Direct)
EP (2) EP3421051B1 (Direct)
JP (1) JP6291495B2 (Direct)
KR (1) KR101742406B1 (Direct)
CN (1) CN104661684B (Direct)
AR (2) AR092368A1 (Direct)
AU (1) AU2013303826B2 (Direct)
BR (1) BR112015003227B1 (Direct)
CA (1) CA2881420C (Direct)
DK (2) DK3421051T3 (Direct)
ES (2) ES2700824T3 (Direct)
FI (1) FIC20220032I1 (Direct)
FR (1) FR22C1037I2 (Direct)
HU (3) HUE041381T2 (Direct)
IL (1) IL237066B (Direct)
IN (1) IN2015DN00694A (Direct)
LU (1) LUC00273I2 (Direct)
MX (1) MX363511B (Direct)
MY (1) MY167579A (Direct)
NL (1) NL301188I2 (Direct)
NO (1) NO2022034I1 (Direct)
NZ (1) NZ704490A (Direct)
PE (1) PE20150464A1 (Direct)
PH (1) PH12015500243B1 (Direct)
PL (2) PL2885007T3 (Direct)
PT (2) PT3421051T (Direct)
RU (2) RU2645071C2 (Direct)
SA (1) SA515360035B1 (Direct)
SG (1) SG11201500566XA (Direct)
SI (2) SI2885007T1 (Direct)
TW (1) TWI480049B (Direct)
WO (1) WO2014027302A1 (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN00694A (Direct) 2012-08-16 2015-06-26 Pfizer
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL246738B2 (en) * 2014-01-21 2024-08-01 Pfizer Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX382438B (es) 2014-01-21 2025-03-13 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos
CA2939416A1 (en) * 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
PL3116887T3 (pl) 2014-03-13 2021-09-06 Universität Basel Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną
PT3244917T (pt) 2015-01-15 2023-05-31 Pfizer Composições imunogénicas para utilização em vacinas pneumocócicas
MX368897B (es) * 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
KR102690378B1 (ko) * 2015-06-08 2024-08-01 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제
EP4649956A2 (en) * 2015-07-21 2025-11-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2020533299A (ja) 2017-09-07 2020-11-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キャリアタンパク質へのコンジュゲーションのための肺炎球菌多糖の製剤方法
US11491216B2 (en) 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11147864B2 (en) 2018-02-05 2021-10-19 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
EP3768309A4 (en) * 2018-03-23 2021-12-01 Koranex Capital PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS
CN111989114A (zh) 2018-04-18 2020-11-24 Sk生物科学株式会社 肺炎链球菌的荚膜多糖以及其免疫原性缀合物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (zh) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法
JP2021087420A (ja) 2019-11-01 2021-06-10 ファイザー・インク Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ組成物およびその方法
KR20220144393A (ko) 2020-02-21 2022-10-26 화이자 인코포레이티드 당류의 정제
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20230096033A (ko) 2020-10-27 2023-06-29 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
AU2021373358B2 (en) 2020-11-04 2026-01-08 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
US20250281601A1 (en) 2021-05-03 2025-09-11 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998056942A1 (en) 1997-06-12 1998-12-17 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
ES2544979T3 (es) * 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Vacuna de conjugado de polisacárido-CRM197 meningocócica tri- o tetravalente
JP2005508143A (ja) 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
US6995001B2 (en) * 2002-10-03 2006-02-07 Wyeth Holdings Corporation Processing for preparing monoprotected diols from symmetric diols
EP1601381A2 (en) 2003-03-07 2005-12-07 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1735321B1 (en) * 2004-04-14 2008-10-08 Wyeth Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
KR101298053B1 (ko) 2005-04-08 2013-08-20 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR101441368B1 (ko) * 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
KR20080106225A (ko) * 2006-03-07 2008-12-04 와이어쓰 마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
DE102006026436A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности
MX2012000045A (es) * 2009-06-22 2012-01-30 Wyeth Llc Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de serotipo 5 y 8 de staphylococcus aureus.
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース６−リン酸受容体を標的とする化合物
PT2503995T (pt) * 2009-11-24 2017-11-23 Grifols Therapeutics Inc Métodos de liofilização, composições e kits
CN103391714A (zh) * 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
MX358840B (es) * 2011-09-07 2018-09-05 Prolynx Llc Hidrogeles con reticulación biodegradable.
IN2015DN00694A (Direct) * 2012-08-16 2015-06-26 Pfizer
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates

Also Published As

Publication number Publication date
HUS2200034I1 (hu) 2022-08-28
NZ704490A (en) 2017-07-28
US20180221467A1 (en) 2018-08-09
IL237066B (en) 2019-03-31
PT3421051T (pt) 2020-06-26
PL3421051T3 (pl) 2020-10-05
MX363511B (es) 2019-03-26
RU2016136630A (ru) 2018-12-11
SA515360035B1 (ar) 2015-09-15
MX2015001992A (es) 2015-10-05
EP3421051B1 (en) 2020-05-13
HUE041381T2 (hu) 2019-05-28
EP2885007B1 (en) 2018-10-10
US20230355735A1 (en) 2023-11-09
HUE049531T2 (hu) 2020-10-28
CA2881420C (en) 2016-11-15
NO2022034I1 (no) 2022-08-04
US11723965B2 (en) 2023-08-15
EP2885007A1 (en) 2015-06-24
SI2885007T1 (sl) 2018-12-31
US20150216996A1 (en) 2015-08-06
SG11201500566XA (en) 2015-04-29
RU2645071C2 (ru) 2018-02-15
AR134188A2 (es) 2025-12-10
NL301188I2 (nl) 2024-05-15
BR112015003227B1 (pt) 2020-10-27
PH12015500243A1 (en) 2015-03-30
RU2724840C2 (ru) 2020-06-25
FR22C1037I1 (fr) 2022-09-09
CN104661684A (zh) 2015-05-27
US11110160B2 (en) 2021-09-07
SI3421051T1 (sl) 2020-08-31
PT2885007T (pt) 2018-12-10
AU2013303826B2 (en) 2017-06-29
US20220096619A1 (en) 2022-03-31
US9517274B2 (en) 2016-12-13
ES2800479T3 (es) 2020-12-30
AU2013303826A1 (en) 2015-02-12
US12447203B2 (en) 2025-10-21
PE20150464A1 (es) 2015-04-25
US10583187B2 (en) 2020-03-10
KR101742406B1 (ko) 2017-05-31
BR112015003227A2 (pt) 2017-07-04
KR20150041139A (ko) 2015-04-15
DK2885007T3 (en) 2018-12-03
PL2885007T3 (pl) 2019-02-28
TWI480049B (zh) 2015-04-11
CN104661684B (zh) 2018-03-20
TW201420115A (zh) 2014-06-01
LUC00273I2 (Direct) 2025-05-12
US20200246448A1 (en) 2020-08-06
CA2881420A1 (en) 2014-02-20
JP6291495B2 (ja) 2018-03-14
ES2700824T3 (es) 2019-02-19
IN2015DN00694A (Direct) 2015-06-26
US20170224804A1 (en) 2017-08-10
EP3421051A1 (en) 2019-01-02
DK3421051T3 (da) 2020-06-22
RU2016136630A3 (Direct) 2019-12-30
PH12015500243B1 (en) 2019-05-31
AR092368A1 (es) 2015-04-15
JP2015524839A (ja) 2015-08-27
US9950054B2 (en) 2018-04-24
RU2015103017A (ru) 2016-10-10
HK1210021A1 (en) 2016-04-15
FIC20220032I1 (fi) 2022-08-05
WO2014027302A1 (en) 2014-02-20
MY167579A (en) 2018-09-20

Similar Documents

Publication Publication Date Title
FR22C1037I2 (fr) Procedes de glycoconjugaison et compositions
DK2935299T3 (da) Glycokonjugationsfremgangsmåde
PT3725778T (pt) Formulações de enzalutamida
SMT202100154T1 (it) Composizioni e metodi per identificare precisamente mutazioni
EP2876220A4 (en) DREDGING
IL261264B (en) Purification of iduronate-2 sulfatase
DK3187586T3 (da) Inducerbar co-ekspressionssystem
PT2836588T (pt) Bioproteção usando estirpes de lactobacilo paracasei
BR112014032798A2 (pt) composição
BR112015001562A2 (pt) biotinas e composições
ME03413B (me) Kompozicije које sadrže peg i askorbat
EP2878951A4 (en) ANALYTICAL DEVICE
BR112014020547A2 (pt) composições oleosas e métodos de produção
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
IT1402519B1 (it) Manichino migliorato
EP2878228A4 (en) EASEL
BR112014032712A2 (pt) composição
HUE049445T2 (hu) Új kompozíciók
DK2811828T3 (da) Adjuvanssammensætninger
EP2837670A4 (en) Fluorobiphenyl-containing composition
EP2823074A4 (en) NICKEL-ALUMINUM-zirconium alloys
CO7071132A2 (es) Composiciones de acción prolongada
DK2800573T3 (da) Oftalmologisk sammensætning
UA22863S (uk) Агрегат ґрунтообробний
EP2877065A4 (en) MANNEQUIN